Last reviewed 2026-05-23 · How we verify

Ethyltryptamine (ETRYPTAMINE)

Phase 2 active Small molecule ✓ Verified May 2026

Ethyltryptamine (generic name: ETRYPTAMINE) is a etryptamine drug. It is currently in Phase 2 development.

ETRYPTAMINE is a serotonin receptor agonist that works by binding to and activating serotonin receptors in the brain.

Ethyltryptamine is a small molecule with the synonyms .ALPHA.ET, ETRIPTAMINA, ETRYPTAMINE, ETRYPTAMINE, MONASE, and NSC-88061.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETRYPTAMINE
Drug class	etryptamine
Target	Sodium-dependent dopamine transporter, Sodium-dependent serotonin transporter, Transporter
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different neighborhoods. ETRYPTAMINE is like a key that unlocks certain neighborhoods, allowing them to communicate with each other in a way that can help with mood and other functions. By activating serotonin receptors, ETRYPTAMINE can help regulate mood, appetite, and other processes.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ethyltryptamine CI brief — competitive landscape report
Ethyltryptamine updates RSS · CI watch RSS

Frequently asked questions about Ethyltryptamine

What is Ethyltryptamine?

Ethyltryptamine (ETRYPTAMINE) is a etryptamine drug.

How does Ethyltryptamine work?

ETRYPTAMINE is a serotonin receptor agonist that works by binding to and activating serotonin receptors in the brain.

What is the generic name of Ethyltryptamine?

ETRYPTAMINE is the generic (nonproprietary) name of Ethyltryptamine.

What drug class is Ethyltryptamine in?

Ethyltryptamine belongs to the etryptamine class. See all etryptamine drugs at /class/etryptamine.

What development phase is Ethyltryptamine in?

Ethyltryptamine is in Phase 2.

What does Ethyltryptamine target?

Ethyltryptamine targets Sodium-dependent dopamine transporter, Sodium-dependent serotonin transporter, Transporter and is a etryptamine.

Drug class: All etryptamine drugs
Target: All drugs targeting Sodium-dependent dopamine transporter, Sodium-dependent serotonin transporter, Transporter
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing